Home Compare NOVN.SW vs RMD
Stock Comparison · Comparison

Novartis vs ResMed: Which Stock Looks Stronger in 2026?

ResMed holds the cleaner structural position, with the lead spread across growth and profitability. Novartis does not offset that deficit through any equally strong structural edge elsewhere. In the market, Novartis carries the stronger setup — intact trend against ResMed's broken trend. That leaves a split case: the structural lead stays with ResMed, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

This is not just a one-metric split: both growth and profitability materially support the lead. ResMed Inc. leads by 32 points on the overall comparison score.

Trajectory Similarity
0.67
Moderately similar
Peer-set rank: #6
within Novartis AG's functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

The pair shares a valid long-term profile match, but the trajectories are not especially close.

The strongest overlap appears in revenue stability and capital structure.

Similarity drivers
revenue stabilitycapital structure
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
NOVN.SW
Novartis AG
55
Peer-Score
Signal qualityHigh
vs
RMD
ResMed Inc.
87
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: NOVN.SW vs RMD Profitability 60 100 Stability 78 72 Valuation 55 84 Growth 22 86 NOVN.SW RMD
Gap Ranking
#1 Growth +64
#2 Profitability +40
#3 Valuation +29
#4 Stability +6
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for NOVN.SW and RMD Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer NOVN.SWRMD Relative valuation Structural strength

ResMed Inc. looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
On growth, ResMed Inc. ranks near the top of the group; Novartis AG sits in the weaker half.
Profitability
On profitability, the same pattern holds: both are strong, but ResMed Inc. still leads clearly.
Growth — Dominant Gap
NOVN.SW
22
RMD
86
Gap+64in favour of RMD

Earnings growth is one contributing factor within the growth lead.

What keeps the gap from being one-sided

On the market side, Novartis carries the stronger trend while ResMed's trend has broken — the market setup does not confirm the structural advantage.

What this means for the comparison

The lead is built on both growth and profitability, making it broader than a single-dimension result.

Explore full peer positioning in AssetNext

Break down the NOVN.SW vs RMD comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-and-profitability comparisons

Explore how NOVN.SW and RMD each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.